Search

Your search keyword '"Donckier, V."' showing total 355 results
Start Over Author "Donckier, V."
355 results on '"Donckier, V."'

1. Histopathological growth patterns of neuroendocrine tumor liver metastases

Author

Meyer, Y., Bohlok, A., Olthof, P., Donckier, V., Doukas, M., Lucidi, V., Vermeulen, Peter, Grunhagen, D., Verhoef, C., Surgery, and Pathology

Subjects
Cancer Research, Oncology, SDG 3 - Good Health and Well-being, Human medicine, General Medicine
Abstract

Histopathological growth patterns (HGPs) of liver metastases represent a potential biomarker for prognosis after resection. They have never been studied in neuroendocrine tumor liver metastases (NETLM). This study evaluated if distinct HGPs can be observed in resected NETLM and if they have prognostic value. Sixty-three patients who underwent resection of NETLM between 01–01-2001 and 31–12-2021 were retrospectively included. HGPs were scored on Haematoxylin&Eosin slides using light microscopy, distinguishing desmoplastic- (dHGP), pushing- (pHGP) and replacement HGP (rHGP). Average HGP scores were calculated per patient. Each patient was classified according to predominant HGP. Overall and Disease-Free Survival (OS and DFS) were evaluated through Kaplan–Meier analysis and Cox regression. Eighteen patients had predominant dHGP (29%), 33 had predominant pHGP (52%) and 11 had predominant rHGP (17%). One patient had mixed HGP (2%). Five-year OS was 76% (95%CI: 66–87%) for the overall cohort. Five-year OS was 92% (95%CI: 77–100%) for dHGP, was 73% (95%CI: 59–91%) for pHGP, 50% (95%CI: 25–100%) for rHGP. Five-year DFS was 39% (95%CI: 19–83%) for dHGP, 44% (95%CI: 27–71%) for rHGP and 50% (95%CI: 23–100%) for pHGP. There was no significant association between HGP and OS or DFS in multivariable analysis. Distinct HGPs could be identified in NETLM. In patients who underwent resection of NETLM, no association was found between HGPs and postoperative survival. Half of the patients with NETLM have a predominant pushing growth pattern, which is a rare growth pattern in liver metastases from breast and colorectal cancer.

Published
2023

2. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights

Author

Latacz, E., Höppener, D., Bohlok, A., Leduc, S., Tabariès, S., Moro, C., Lugassy, C., Nyström, H., Bozóky, B., Floris, G., Geyer, N., Brodt, P., Llado, L., Mileghem, L. Van, Schepper, M. De, Majeed, A.W., Lazaris, A., Dirix, P., Zhang, Qianni, Petrillo, S.K., Vankerckhove, S., Joye, I., Meyer, Y., Gregorieff, A., Roig, N.R., Vidal-Vanaclocha, F., Denis, L., Oliveira, R.C., Metrakos, P., Grünhagen, D.J., Nagtegaal, I.D., Mollevi, D.G., Jarnagin, W.R., D'Angelica, M.I., Reynolds, A.R., Doukas, M., Desmedt, C., Dirix, L., Donckier, V., Siegel, P.M., Barnhill, R., Gerling, M., Verhoef, C., Vermeulen, P.B., Latacz, E., Höppener, D., Bohlok, A., Leduc, S., Tabariès, S., Moro, C., Lugassy, C., Nyström, H., Bozóky, B., Floris, G., Geyer, N., Brodt, P., Llado, L., Mileghem, L. Van, Schepper, M. De, Majeed, A.W., Lazaris, A., Dirix, P., Zhang, Qianni, Petrillo, S.K., Vankerckhove, S., Joye, I., Meyer, Y., Gregorieff, A., Roig, N.R., Vidal-Vanaclocha, F., Denis, L., Oliveira, R.C., Metrakos, P., Grünhagen, D.J., Nagtegaal, I.D., Mollevi, D.G., Jarnagin, W.R., D'Angelica, M.I., Reynolds, A.R., Doukas, M., Desmedt, C., Dirix, L., Donckier, V., Siegel, P.M., Barnhill, R., Gerling, M., Verhoef, C., and Vermeulen, P.B.

Abstract

Item does not contain fulltext, The first consensus guidelines for scoring the histopathological growth patterns (HGPs) of liver metastases were established in 2017. Since then, numerous studies have applied these guidelines, have further substantiated the potential clinical value of the HGPs in patients with liver metastases from various tumour types and are starting to shed light on the biology of the distinct HGPs. In the present guidelines, we give an overview of these studies, discuss novel strategies for predicting the HGPs of liver metastases, such as deep-learning algorithms for whole-slide histopathology images and medical imaging, and highlight liver metastasis animal models that exhibit features of the different HGPs. Based on a pooled analysis of large cohorts of patients with liver-metastatic colorectal cancer, we propose a new cut-off to categorise patients according to the HGPs. An up-to-date standard method for HGP assessment within liver metastases is also presented with the aim of incorporating HGPs into the decision-making processes surrounding the treatment of patients with liver-metastatic cancer. Finally, we propose hypotheses on the cellular and molecular mechanisms that drive the biology of the different HGPs, opening some exciting preclinical and clinical research perspectives.

Published
2022

13. Laparoscopic liver resection of benign liver tumors

Author

Descottes, B., Glineur, D., Lachachi, F., Valleix, D., Paineau, J., Hamy, A., Morino, M., Bismuth, H., Castaing, D., Savier, E., Honore, P., Detry, O., Legrand, M., Azagra, J.S., Goergen, M., Ceuterick, M., Marescaux, J., Mutter, D., Hemptinne, B., Troisi, R., Weerts, J., Dallemagne, B., Jehaes, C., Gelin, M., Donckier, V., Aerts, R., Topal, B., Bertrand, C., Mansvelt, B., Krunckelsven, L., Herman, D., Kint, M., Totte, E., Schockmel, R., and Gigot, J.F.

Published
2003
Full Text
View/download PDF

16. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial

Author

Garlipp, B., Gibbs, P., Van Hazel, G. A., Jeyarajah, R., Martin, R. C. G., Bruns, C. J., Lang, H., Manas, D. M., Ettorre, G. M., Pardo, F., Donckier, V., Benckert, C., van Gulik, T. M., Goere, D., Schoen, M., Pratschke, J., Bechstein, W. O., de la Cuesta, A. M., Adeyemi, S., Ricke, J., Seidensticker, M., Garlipp, B., Gibbs, P., Van Hazel, G. A., Jeyarajah, R., Martin, R. C. G., Bruns, C. J., Lang, H., Manas, D. M., Ettorre, G. M., Pardo, F., Donckier, V., Benckert, C., van Gulik, T. M., Goere, D., Schoen, M., Pratschke, J., Bechstein, W. O., de la Cuesta, A. M., Adeyemi, S., Ricke, J., and Seidensticker, M.

Abstract

Background Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. Methods Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic disease status, and information on clinical and scanning time points. Technical resectability was defined as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient's liver metastases as surgically removable. Results Some 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline difference in the proportion of technically resectable liver metastases between SIRT (29, 11 center dot 9 per cent) and control (25, 11 center dot 0 per cent) arms (P = 0 center dot 775). At follow-up, significantly more patients in both arms were deemed technically resectable compared with baseline: 159 of 472 (33 center dot 7 per cent) versus 54 of 472 (11 center dot 4 per cent) respectively (P = 0 center dot 001). More patients were resectable in the SIRT than in the control arm: 93 of 244 (38 center dot 1 per cent) versus 66 of 228 (28 center dot 9 per cent) respectively (P < 0 center dot 001). Conclusion Adding SIRT to chemotherapy may improve the resectability of unresectable CRLM.

Published
2019

17. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.

Author

Garlipp, B, Gibbs, P, Van Hazel, GA, Jeyarajah, R, Martin, RCG, Bruns, CJ, Lang, H, Manas, DM, Ettorre, GM, Pardo, F, Donckier, V, Benckert, C, van Gulik, TM, Goéré, D, Schoen, M, Pratschke, J, Bechstein, WO, de la Cuesta, AM, Adeyemi, S, Ricke, J, Seidensticker, M, Garlipp, B, Gibbs, P, Van Hazel, GA, Jeyarajah, R, Martin, RCG, Bruns, CJ, Lang, H, Manas, DM, Ettorre, GM, Pardo, F, Donckier, V, Benckert, C, van Gulik, TM, Goéré, D, Schoen, M, Pratschke, J, Bechstein, WO, de la Cuesta, AM, Adeyemi, S, Ricke, J, and Seidensticker, M

Abstract

BACKGROUND: Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. METHODS: Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic disease status, and information on clinical and scanning time points. Technical resectability was defined as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient's liver metastases as surgically removable. RESULTS: Some 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline difference in the proportion of technically resectable liver metastases between SIRT (29, 11·9 per cent) and control (25, 11·0 per cent) arms (P = 0·775). At follow-up, significantly more patients in both arms were deemed technically resectable compared with baseline: 159 of 472 (33·7 per cent) versus 54 of 472 (11·4 per cent) respectively (P = 0·001). More patients were resectable in the SIRT than in the control arm: 93 of 244 (38·1 per cent) versus 66 of 228 (28·9 per cent) respectively (P < 0·001). CONCLUSION: Adding SIRT to chemotherapy may improve the resectability of unresectable CRLM.

Published
2019

21. SUN-PO116: Fat Quality Correlates with Prognosis of Esophageal Cancer

Author

Anciaux, M., primary, Van Gossum, A., additional, Wenglinski, C., additional, Ameye, L., additional, Guiot, T., additional, Flamen, P., additional, Demetter, P., additional, Deleporte, A., additional, Paesmans, M., additional, Donckier, V., additional, Hendlisz, A., additional, and Vandeputte, C., additional

Published
2019
Full Text
View/download PDF

22. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial

Author

Garlipp, B, primary, Gibbs, P, additional, Van Hazel, G A, additional, Jeyarajah, R, additional, Martin, R C G, additional, Bruns, C J, additional, Lang, H, additional, Manas, D M, additional, Ettorre, G M, additional, Pardo, F, additional, Donckier, V, additional, Benckert, C, additional, Gulik, T M, additional, Goéré, D, additional, Schoen, M, additional, Pratschke, J, additional, Bechstein, W O, additional, Cuesta, A M, additional, Adeyemi, S, additional, Ricke, J, additional, and Seidensticker, M, additional

Published
2019
Full Text
View/download PDF

28. REsect: Blinded assessment of resectability of previously unresectable colorectal cancer liver metastases following chemotherapy±Y90-RadioEmbolization

Author

Garlipp, B., primary, Gibbs, P., additional, van Hazel, G., additional, Jeyarajah, R., additional, Martin, R., additional, Bruns, C., additional, Lang, H., additional, Manas, D., additional, Ettorre, G.M., additional, Pardo Sanchez, F., additional, Donckier, V., additional, Benckert, C., additional, van Gulik, T., additional, Goéré, D., additional, Schön, M., additional, Pratschke, J., additional, Bechstein, W., additional, Adeyemi, S., additional, and Seidensticker, M., additional

Published
2019
Full Text
View/download PDF

36. Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer

Author

Flament, A., primary, Hendlisz, A., additional, Shaza, L., additional, Aspeslagh, S., additional, Vouche, M., additional, Donckier, V., additional, Awada, A., additional, Machiels, J.-P., additional, van den Eynde, M., additional, Canon, J.-L., additional, Carrasco, J., additional, Lonez, C., additional, and Lehmann, F.F., additional

Published
2018
Full Text
View/download PDF

38. Selective internal radiation therapy (SIRT) promotes the recruitment of tumor-infiltrating lymphocytes and enhances cytotoxic activity in hepatocellular carcinoma

Author

Craciun, L., primary, De Wind, R., additional, Demetter, P., additional, Lucidi, V., additional, Michiels, S., additional, Garaud, S., additional, Naveaux, C., additional, Gomez Galdon, M., additional, Hendlisz, A., additional, Willard Gallo, K., additional, Flamen, P., additional, Larsimont, D., additional, and Donckier, V., additional

Published
2017
Full Text
View/download PDF

39. Erratum: Laparoscopic liver resection of benign liver tumors

Author

Descottes, B., Glineur, D., Lachachi, F., Valleix, D., Paineau, J., Hamy, A., Morino, M., Bismuth, H., Castaing, D., Savier, E., Honore, P., Detry, O., Legrand, M., Azagra, J.S., Goergen, M., Ceuterick, M., Marescaux, J., Mutter, D., Hemptinne, B., Troisi, R., Weerts, J., Dallemagne, B., Jehaes, C., Gelin, M., Donckier, V., Aerts, R., Topal, B., Bertrand, C., Mansvelt, B., Krunckelsven, L., Herman, D., Kint, M., Totte, E., Schockmel, R., and Gigot, J.F.

Published
2003
Full Text
View/download PDF

41. Near infrared fluorescence imaging after intraoperative injection of indocyanine green to improve the staging during cytoreductive surgery for peritoneal carcinomatosis of colorectal origin: results of a pilot prospective study (NCT02032485)

Author

Liberale, G., primary, Vankerckhove, S., additional, Gomez Galdon, M., additional, Ahmed, B., additional, El Nakadi, I., additional, Larsimont, D., additional, Donckier, V., additional, and Bourgeois, P., additional

Published
2017
Full Text
View/download PDF

42. Feasibility and safety of a therapeutic strategy using selective transarterial radioembolization followed by surgery for hepatocellular carcinoma in cirrhotic patients

Author

Lemaire, M., primary, Lucidi, V., additional, Katsanos, G., additional, Bouazza, F., additional, Gomez Galdon, M., additional, Larsimont, D., additional, Delatte, P., additional, Vouche, M., additional, Hendlisz, A., additional, Flamen, P., additional, and Donckier, V., additional

Published
2017
Full Text
View/download PDF

48. Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT)

Author

Hoogduijn, M.J., Popp, F.C., Grohnert, A., Crop, M.J., Rhijn, M. van, Rowshani, A.T., Eggenhofer, E., Renner, P., Reinders, M.E., Rabelink, T.J., Laan, L.J.W. van der, Dor, F.J.M.F., IJzermans, J.N.M., Genever, P.G., Lange, C., Durrbach, A., Houtgraaf, J.H., Christ, B., Seifert, M., Shagidulin, M., Donckier, V., Deans, R., Ringden, O., Perico, N., Remuzzi, G., Bartholomew, A., Schlitt, H.J., Weimar, W., Baan, C.C., Dahlke, M.H., MISOT Study Grp, Internal Medicine, Surgery, and Cardiology

Subjects
Oncology, medicine.medical_specialty, Pathology, T-Lymphocytes, medicine.medical_treatment, Cell Culture Techniques, Cell- and Tissue-Based Therapy, Mesenchymal stem cell Solid organ transplantation Clinical trial MISOT versus-host-disease in-vitro survival repair vivo, Liver transplantation, Mesenchymal Stem Cell Transplantation, Organ transplantation, Immunophenotyping, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Kidney transplantation, 030304 developmental biology, Immunosuppression Therapy, 0303 health sciences, Transplantation, business.industry, Graft Survival, Mesenchymal stem cell, Mesenchymal Stem Cells, Immunosuppression, Organ Transplantation, medicine.disease, Kidney Transplantation, Liver Transplantation, 3. Good health, Clinical trial, surgical procedures, operative, 030220 oncology & carcinogenesis, Safety, business, Solid organ transplantation
Abstract

There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or underway. At a recent meeting of the MISOT consortium (MSC In Solid Organ Transplantation) the advances of these studies were evaluated and mechanisms underlying the potential effects of MSC discussed. Continued discussion is required for definition of safety and eventually efficacy endpoints for MSC therapy in solid organ transplantation.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results